What is the lipid form of amphotericin B that is less nephrotoxic?

Liposomal amphotericin B is a formulation designed to reduce the nephrotoxic effects commonly associated with conventional amphotericin B, specifically the deoxycholate form. This liposomal formulation encapsulates the drug within lipid layers, which help to alter its distribution and pharmacokinetics. As a result, liposomal amphotericin B has improved tolerability, allowing for higher doses to be administered with a lower risk of kidney damage compared to the traditional form.

Additionally, this lipid-based preparation enhances the drug's therapeutic efficacy by targeting fungal cells more effectively while sparing renal tissues, which makes it a preferable option in patients who are at risk of renal impairment or those who have pre-existing kidney disease. The use of liposomal formulations in antifungal therapy is well-established, and the benefits in terms of safety profile and efficacy are key reasons why liposomal amphotericin B is favored in clinical settings for treatment of serious fungal infections.